AFFF cancer lawsuit

Firefighting Foam Is A Deadly Carcinogenic Substance That Disrupts Normal Cellular Functions

Studies prove that PFAS exposure causes liver, pancreatic, and testicular cancers

Monday, April 1, 2024 - Due to possible health risks, firefighting foam, an essential tool in combating fires, especially those involving flammable liquids, has come under investigation and multiple firefighting foam lawsuits. There is strong evidence from recent scientific studies that certain AFFF foams contain chemicals that raise the risk of cancer in firefighters. The purpose of firefighting foams, especially aqueous film-forming foams (AFFFs), is to suppress fires by smothering the fire by producing a barrier between the fuel and the air. These foams work particularly well against oil and gasoline flames, which are frequent in industrial and aircraft mishaps. Nevertheless, per and poly-fluoroalkyl substances (PFAS), a class of synthetic compounds resistant to heat, oil, and water, are present in AFFFs. Although AFFF is useful in combating fires, PFAS compounds are environmentally persistent.

The potential carcinogenicity of PFAS comes from its ability to disrupt normal cellular functions. Scientific research has shown that PFAS can interact with cellular receptors and influence gene expression, leading to uncontrolled cell growth and cancer. Animal studies have provided evidence that PFAS exposure is linked to the development of several types of cancer, including liver, pancreatic, and testicular cancers. While translating findings from animal models to humans requires caution, these studies suggest a plausible link between PFAS and cancer risk. Epidemiological studies among firefighting populations have further supported the concern over PFAS exposure. Firefighters, who are frequently exposed to AFFFs in their line of duty, have been found to have higher rates of certain cancers compared to the general population. A significant body of research indicates elevated incidences of prostate, kidney, and testicular cancer among firefighters. Moreover, studies have found higher concentrations of PFAS in the blood of firefighters compared to the general population, providing a direct link between occupational exposure and PFAS accumulation in the body.

The evidence has prompted different kinds of action. Stricter rules for the use of foams containing PFAS have been demanded by firefighting associations and health groups, who are also pushing for the creation and usage of safer substitutes. As a result, some governments have started to phase out the usage of AFFFs and have allocated funds for the development of safe and efficient firefighting techniques. The move away from foams that contain PFAS presents substantial obstacles notwithstanding these efforts. Alternative foams might not be as successful in putting out some kinds of fires, which could jeopardize firefighting skills and endanger public safety. Furthermore, residual pollution from the previous usage of foam will remain an issue for many years to come due to the persistence of PFAS in the environment.

The ongoing scientific research into the health impacts of firefighting foams highlights a critical tension in public safety efforts. On one hand, AFFFs are invaluable tools in protecting lives and property from fire. On the other, their chemical composition poses significant health risks to the very individuals who rely on them for safety. Balancing these concerns requires a multifaceted approach, including continued research into the health effects of PFAS, development of safer firefighting methods, and policies that protect both firefighters and the public from chemical exposures.

Information provided by AFFFLawsuitCenter.com, a website devoted to providing news about AFFF and PFAS cancer, lymphoma and leukaemia claims, including a free no-cost, no-obligation AFFF Lawsuit Claim.

More Recent AFFF Lawsuit News:

View all AFFF Lawsuit News

No-Cost, No-Obligation Claim Review for Persons or Families of Persons Who Developed Cancer, Lymphoma or Leukaemia After Exposure to Firefighting Foam

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.


Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.